The Russian laboratory Nova Medica and Horus Pharma, French laboratory specialising in ophthalmology, have entered into an exclusive distribution agreement in Russia and the Commonwealth Independent States (CIS).
Nova Medica will distribute a portfolio of ophthalmologic speciality products including a range of preservative-free dermatological medical devices, food supplements to improve vision and single-dose eye drops indicated in corneal scarring. Marketing of these products will begin in 2015.
Claude Claret, CEO of Horus Pharma, enthusiastically welcomes this new partnership, which opens new therapeutic perspectives in Russia :
"With its expertise in Biotech and its location in a high growth market, NovaMedica is an effective partner to ensure the registration and commercialisation of our products in Russia. We are pleased to now offer patients and practitioners in Russia advanced therapeutic solutions."
Fabrice Egros, Chief Operating Officer of NovaMedica, also welcomed the agreement reached with Horus Pharma:
"By continually expanding our product portfolio through our partnerships with Clearside Biomedical, ReVision Optics, SiFi and now Horus Pharma, NovaMedica offers a unique combination of ophthalmology speciality products, covering a wide spectrum of eye diseases."
NovaMedica is a Russian pharmaceutical company established in 2012 by DRI Holdings Limited, a portfolio company of Domain Associates LLC, and RUSNANO, which implements Russian government policy of fostering the development of hi-tech industries. The company’s strategy is aimed at localizing production of a wide range of new medicines and technologies in the Russian market, including screening and registration of new pharmaceuticals, and the creation of innovative GMP-standard manufacturing facilities.
For more details please visit www.novamedica.com